Latest Osteonecrosis of the jaw Stories
SILVER SPRING, Md., June 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) Osteoporosis is a disease in which the bones become weak and are more likely to break. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, 80 percent of the people in the United...
CHICAGO, May 26 /PRNewswire-USNewswire/ -- People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of The Journal of the American Dental Association (JADA). Use of bisphosphonates has been associated with a small risk of developing bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or after the...
A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.Bone marrow stem cells have been shown in several experimental studies to have beneficial effects in disease models of MS. The research team, led by Neil Scolding, Burden Professor of Clinical Neurosciences for the University of Bristol and North Bristol NHS Trust, have now completed a small trial in...
Studies find possible links between prolonged bisphosphonate treatmentsBisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).Bisphosphonates are designed to slow or stop the bone loss...
Studies find possible links between prolonged bisphosphonate treatments and atypical fractures in post-menopausal women NEW ORLEANS, March 10 /PRNewswire-USNewswire/ -- Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the...
SEATTLE, March 5 /PRNewswire/ -- Women who take some types of bone-building drugs used to prevent and treat osteoporosis may be at lower risk of breast cancer, according to a study by U.S. researchers published today in the British Journal of Cancer. The study found that women who used bisphosphonate drugs, such as Fosamax, Boniva and Zomita, for more than two years had a nearly 40 percent reduction in risk as compared to those who did not, according to lead author Polly Newcomb, Ph.D.,...
SEATTLE "“ Women who take some types of bone-building drugs used to prevent and treat osteoporosis may be at lower risk of breast cancer, according to a study by U.S. researchers published today in the British Journal of Cancer. The study found that women who used bisphosphonate drugs, such as Fosamax, Boniva and Zomita, for more than two years had a nearly 40 percent reduction in risk as compared to those who did not, according to lead author Polly Newcomb, Ph.D., M.P.H., head of the...
SAN ANTONIO, Dec. 10 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced further detailed results from a Phase 3, head-to-head trial of denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer. In this trial denosumab met both primary and secondary endpoints and demonstrated superiority for both delaying the time to the first on-study skeletal related events (SRE) (fracture, radiation to bone, surgery to bone, or spinal...
URBANA, Ill., Oct. 29 /PRNewswire/ -- Health Alliance Medical Plans, Inc., a leading provider-sponsored health insurer, covering more than 310,000 commercial plan members in Illinois and Iowa, has announced positive outcomes from a nine-month Fracture Protection Program pilot launched in partnership with the makers of Actonel, a prescription drug for the treatment and prevention of postmenopausal osteoporosis. Through the program with Health Alliance, the makers of Actonel agreed to...
THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European...
